Moreover, Apatinib inhibits the upstream of STAT3, vascular endothelial growth factor receptor-2 (VEGFR2), to decrease PD-L2 expression through the RhoA-ROCK-LIMK2 axis, eventually, suppressing tumour migration, invasion, and cytoskeletal rearrangement in osteosarcoma [51]. Here, LIMK2 is linked to osteosarcoma.